Azurity Patent-Cliff Exposure & CMS Drug Spending Portfolio
Azurity (US): 41 reconciled FDA prescription therapies (42.0% 2025 to 2030 cliff risk), $229.4M 2024 CMS Part D & Medicaid spend, and 61 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 41 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 42.0% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $229.4M |
| 2024 Medicare Part D Spend | $106.3M |
| 2024 Medicaid Spend | $123.1M |
| California HCAI SB 17 Filings | 61 WAC filings (max 26.4% 2-yr change) |